
Methodology: Every two weeks we collect most relevant posts on LinkedIn for selected topics and create an overall summary only based on these posts. If you´re interested in the single posts behind, you can find them here: https://linktr.ee/thomasallgeyer. Have a great read!
Roughly 18 months, plus proof-of-concept traction. Early user validation and data-rich storytelling now beat polished slide decks. Resources like a VC valuation template and a Fundraising Playbook with 200+ outreach scripts give founders structured tactics in a buyer's market.
AI, defence, nature tech, MedTech and biotech. MedTech investors will fund beyond MVP when safety pathways are clear, and biotech capital follows strong clinical data. Defence tech is gaining prominence, with Baltic voices calling for transparency and dual-use applicability.
Speed, specialised support and flexible cheque sizes at pre-seed. They signal fresh capital formation despite a more selective market. Corporate VCs are also sharpening secondary-share strategies for liquidity, and Web Summit Vancouver framed AI as the main force reshaping venture capital.
How we solve real problems for real clients